leakage, with 15 women (55.6%) becoming completely leak-free at the 1-month follow-up. At the 1-month follow-up visit, 24 subjects (88.9%) expressed their condition's interference with everyday life decreased and 17 patients (62.9%) said the condition did not interfere with their everyday life at all as a result of the treatment.
All results are statistically significant (P<.05). No adverse events were recorded.
All subjects reported improvement in vaginal laxity, from average perception of "very loose" (2.19AE1.08 points prior to treatment) to "moderately tight" (5.74AE0.76 points at the 1-month follow-up visit).
During the follow-up visit, 89% of the patients "agreed" or "strongly agreed" that their SUI condition improved, and 93% of the patients "agreed" or "strongly agreed" that their gratification during intercourse improved. None of the subjects reported dissatisfaction.
Conclusion:
The study confirmed the monopolar radiofrequency method as an effective and safe treatment of SUI and vulvo-vaginal laxity. The treatments were well tolerated by all subjects with no adverse effects.
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| INTRODUCTION

Stress urinary incontinence (SUI) is a condition of involuntary urine
leakage from the urethra considered to be a hygiene and/or social problem. 1 Statistical data show that the most affected part of the population are women, with approximately 35% of all women worldwide affected.
Urinary incontinence (UI) is frequently linked to vulvo-vaginal laxity, which encompasses laxity of both the vaginal introitus and labia majora. This condition is most commonly linked to sexual dissatisfaction due to limited friction, feeling of looseness, and orgasmic dysfunction; all leading to lower sexual gratification during intercourse.
Both of these conditions lead to a decreased quality of life (QoL) including social isolation, decreased self-confidence, and lower sexual gratification during intercourse.
2,3
The major risk factors for the development of SUI and vulvo-vaginal laxity include childbirth, advancing age, hysterectomy, recurrent urinary tract infections, smoking, medications such as diuretics, sedative-hypnotics and alpha blockers, the presence of comorbid diseases, and excessive weight. 2, [4] [5] [6] The conventional methods for treating this condition include medications, pelvic floor muscularity strengthening (exercising and/or electro stimulation), surgical procedures, and lifestyle changes (such as quitting smoking or losing weight). [7] [8] [9] Radiofrequency (RF) is one of the more innovative approaches to treating SUI and vulvo-vaginal laxity. It has gained significant popularity in recent years due to its noninvasiveness, absence of adverse events, and fast results. The mechanism of action is based on elevating the temperature of the treated tissue to initiate biological changes.
RF-generated heat stimulates the tissue matrix of collagen, elastin, and ground substances and results in immediate change in the helical structure of the collagen. Additionally, neocollagenesis and neoelastogenesis are triggered due to micro-inflammatory stimulation of fibroblasts. 10 It is also believed that the production of sex steroid precursor dehydroepiandrosterone (DHEA) is activated. DHEA supports estrogen production in the vulvo-vaginal cells which plays a big role in rejuvenating and stimulating the vaginal tissue and collagen.
The aim of this study was to investigate the efficacy and safety of a monopolar radiofrequency device for transvaginal treatment of SUI and vulvo-vaginal laxity.
| MATERIALS AND METHODS
| Participants
Twenty-seven women aged between 28 and 66 (mean age 44.78AE10.04 years) participated in this nonrandomized, prospective, multicentric study. Only subjects who experienced mild-to-moderate stress urinary incontinence (minimum level 1 in the frequency of leakage based on ICIQ-UI SF form, ie, experiencing leakage at least once a week) and vaginal laxity (maximum level 5 of vulvo-vaginal laxity based on VVLQ questionnaire, ie, defined as no more than "slightly tight") were enrolled. Prior to the study, 19 subjects (70.4%) evaluated their vulvovaginal tightness as "moderately loose" or "very loose," 18 subjects (66.7%) reported they leak urine at least two or three times a week. Twenty-six subjects (96.3%) had a history of at least one prior delivery. The exclusion criteria included the following:
abnormal cell cytology; positive urine culture; bleeding in the vulvovaginal area; pregnancy or breastfeeding; metal implants; unwillingness or incapability to complete the entire study protocol; any other contraindication listed by the device manufacturer. All patients were LALJI AND LOZANOVA | 231
consented. The study was approved by an independent ethics committee.
| Therapy provision
The therapy course consisted of three once-a-week (AE 2 days) treat- 
| Outcome measures and statistic evaluation
The SUI condition was assessed by applying the standardized International Consultation on Incontinence Questionnaire -Urinary Incontinence Short Form (ICIQ-UI SF). 11 Data were collected before the first, after the third (last) treatment and during the 1-month followup visit. Average improvement was calculated.
Vaginal laxity was assessed by nonstandardized subjective vulvovaginal laxity questionnaire (VVLQ) using 7-point Likert scale (BTL Industries Inc.). Data were collected before the first treatment and during the 1-month follow-up visit. Average improvement was calculated.
All outcome data were tested for statistical significance by means of t test, where levels of P<.05 were deemed statistically meaningful.
Patients' satisfaction with the treatment results was evaluated using a 6-point Likert scale satisfaction questionnaire. The questionnaire consisted of the following statements: (1) "My UI has been improved" and (2) "My sexual gratification has been improved", with the following possible answers: strongly disagree (1); disagree (2); slightly disagree (3); slightly agree (4); agree (5), strongly agree (6).
Data were collected after the third (last) treatment and during the 1-month follow-up visit.
| RESULTS
All 27 patients completed the study. All treatment sessions were conducted in accordance with the treatment protocol. No adverse events or side effects were observed.
| Urinary Incontinence
The outcome data and the results from ICIQ-SF and VVLQ are presented in Table 1 .
The average frequency of urine leak improved from "2-3 times a week" (2.15AE1.03 points prior to treatment) to "once a week" All measured results were proven statistically significant (P<.05).
| Vaginal laxity
On a scale of 1-7, the average vulvo-vaginal laxity improved from levels when comparing the baseline to the follow-up visit. 1 month after the last treatment, all (100%) subjects evaluated their vulvovaginal sensation to be slightly, moderately or very tight.
| Patient satisfaction
The data from the satisfaction questionnaire are presented in Figures 1-4 .
Eighty-one percentage of the patients "agree" or "strongly agree"
that their SUI condition improved post-treatment compared to the baseline, and the share increased to 89% during the follow-up visit.
The remaining 19% and 11%, respectively "slightly agreed." None of the subjects reported dissatisfaction (score 0-3).
Seventy-eight percentage of the patients "agree" or "strongly agree"
that their gratification during intercourse improved post-treatment compared to the baseline, and the share increased to 93% during the follow-up visit. The remaining 22% and 7%, respectively, "slightly agreed." None of the subjects reported dissatisfaction (score 0-3).
| CONCLUSION
The study captures significant improvement in the treated conditions at the 1-month follow-up visit. Although further controlled study is needed to confirm the data and evaluate the long-term effects in the endovaginal treatment.
